Article content material
- Prostate-specific membrane antigen (PSMA) is a number one goal for next-generation prostate most cancers therapies, with one FDA-approved drugs and 30 medicines in growth
- Quantitative PSMA-PET imaging is required to find out affected person eligibility for the primary FDA-approved PSMA-targeting drugs and is an inclusion criterion for ongoing trials
BOSTON, Sept. 15, 2024 (GLOBE NEWSWIRE) — Precede Biosciences, an organization impacting the event and use of precision medicines with a first-in-class complete epigenomic liquid biopsy platform, at this time shared the corporate’s scientific poster presentation from the 2024 European Society for Medical Oncology (ESMO) Annual Assembly happening from September 13 to 17, 2024 in Barcelona, Spain.
Article content material
“These knowledge spotlight the flexibility for complete epigenomic profiling to ship a minimally invasive and clinically accessible surrogate of tumor PSMA expression in males with metastatic castration-resistant prostate most cancers,” stated Jacob E. Berchuck, MD, Assistant Professor, Division of Hematology and Medical Oncology, Winship Most cancers Institute of Emory College. “Given PSMA-PET just isn’t equally accessible throughout the USA and throughout the globe, evaluation of PSMA tumor expression from blood might allow optimized affected person identification for the one accepted and the numerous rising medicines concentrating on PSMA.”
“These promising knowledge spotlight the potential of the Precede Bio platform to resolve necessary actionable targets from a easy blood draw,” stated Carl Barrett, Chief Scientific Officer of Precede Bio. “PSMA is the primary goal for the following wave of precision medicines in prostate most cancers, and these knowledge help the promise of our platform to tell on remedy choice on this context. We look ahead to persevering with to work with main teachers and drug builders to advance this necessary work, and on the identical time to proceed our work on different high-value targets, reminiscent of DLL3 and STEAP1, all with the objective of informing remedy choice for medicines in opposition to these targets from the identical 1 mL of plasma.”
Article content material
Knowledge introduced on the 2024 ESMO Annual Assembly will be discovered within the displays part of the firm web site and beneath:
About Precede Biosciences
Precede Biosciences is breaking down the limitations to precision drugs by redefining what will be realized from a easy blood draw. By understanding the elemental biology behind illness at any given second, researchers and clinicians can higher goal medicines to the precise sufferers in each drug growth and scientific observe. Precede Bio seeks to enhance success charges in drug growth and to be part of constructing a future the place each affected person can obtain a fast, minimally invasive prognosis and remedy that’s exact to the biology of their illness. Precede Bio’s platform is obtainable to drug builders and educational researchers. To study extra, go to www.precede.bio or comply with us on X/Twitter and LinkedIn.
Media Contacts:
Donelle M Gregory
media@precede.bio
Adam Silverstein
adam@scientpr.com
Share this text in your social community
